 Heparin
"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in UAMS Profiles by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2021 | 0 | 2 | 2 | | 2020 | 2 | 3 | 5 | | 2018 | 2 | 1 | 3 | | 2017 | 1 | 0 | 1 | | 2016 | 3 | 1 | 4 | | 2015 | 3 | 2 | 5 | | 2014 | 4 | 0 | 4 | | 2013 | 0 | 1 | 1 | | 2012 | 3 | 0 | 3 | | 2011 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2007 | 1 | 1 | 2 | | 2005 | 2 | 0 | 2 | | 2004 | 0 | 2 | 2 | | 2003 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1997 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1995 | 0 | 2 | 2 | | 1993 | 2 | 0 | 2 | | 1992 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Heparin" by people in Profiles over the past ten years.
-
Alturkmani H, Uretsky B, Patel S, Albadaineh M, Alqaisi O, Alaiwah M, Cross M, Abbasi D, Rollefson W. Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary Intervention. Am J Cardiol. 2024 05 01; 218:63-67.
-
Verreault-Julien L, Simsek B, Kostantinis S, Rempakos A, Karacsonyi J, Patel TN, Jefferson BK, Patel M, Poommipanit PB, Uretsky BF, Alaswad K, Gorgulu S, Goktekin O, Khatri J, Khelimskii D, Krestyaninov O, Allana S, Rinfret S, Nicholson WJ, Brilakis ES, Jaber WA. Use of Bivalirudin for Chronic Total Occlusion Percutaneous Intervention: Insights From the PROGRESS-CTO Registry. J Invasive Cardiol. 2023 04; 35(4):E179-E184.
-
Calcaterra G, Bassareo PP, De Gregorio C, Barilla F, Romeo F, Mehta JL. COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art. Curr Cardiol Rev. 2022; 18(5):11-17.
-
Sadeghi S, Kalhor H, Panahi M, Abolhasani H, Rahimi B, Kalhor R, Mehrabi A, Vahdatinia M, Rahimi H. Keratinocyte growth factor in focus: A comprehensive review from structural and functional aspects to therapeutic applications of palifermin. Int J Biol Macromol. 2021 Nov 30; 191:1175-1190.
-
Briggler R, Matherne E, Johnson C, Boehmer K. Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy. J Pharm Pract. 2022 Oct; 35(5):811-816.
-
Omecene NE, Kishk OA, Lardieri AB, Walker LK, Bhutta AT. Comparison of Antithrombin III Products in Pediatric Patients Receiving Extracorporeal Membrane Oxygenation. ASAIO J. 2020 Sep/Oct; 66(9):1042-1047.
-
Nissen AP, Sandhu HK, Perlick AP, Wong VL, Smith TA, Smeds MR, Saqib NU, Martin GH, Miller CC, Charlton-Ouw KM. Heparin-bonded versus standard polytetrafluoroethylene arteriovenous grafts: A Bayesian perspective on a randomized controlled trial for comparative effectiveness. Surgery. 2020 Dec; 168(6):1066-1074.
-
Onuoha C, Barton KD, Wong ECC, Raval JS, Rollins-Raval MA, Ipe TS, Kiss JE, Boral LI, Adamksi J, Zantek ND, Onwuemene OA. Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: A systematic review. Transfusion. 2020 11; 60(11):2714-2736.
-
Corona LE, Singhal U, Hafez K, Herrel LA, Kaffenberger SD, Montgomery JS, Morgan TM, Weizer AZ, Qin Y, Ambani SN. Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. Urol Oncol. 2020 10; 38(10):797.e1-797.e6.
-
Kumar R, Bhandari S, Singh SRK, Malapati S, Cisak KI. Incidence and outcomes of heparin-induced thrombocytopenia in solid malignancy: an analysis of the National Inpatient Sample Database. Br J Haematol. 2020 05; 189(3):543-550.
-
Bhogal S, Mukherjee D, Bagai J, Truong HT, Panchal HB, Murtaza G, Zaman M, Sachdeva R, Paul TK. Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. Cardiovasc Hematol Disord Drug Targets. 2020; 20(1):3-15.
-
Mallidi J, Ulahannan J, Chaubey VK, Atreya AR, Shakoor MT, Fisher D, Garb J, Lotfi A. Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Access Versus Heparin With Transradial Access in Patients With ST segment Elevation Myocardial Infarction. Crit Pathw Cardiol. 2019 09; 18(3):130-134.
-
Onwuemene OA, Zantek ND, Rollins-Raval MA, Raval JS, Kiss JE, Ipe TS, Kuchibhatla M, Pagano MB, Wong ECC. Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey. J Clin Apher. 2019 Oct; 34(5):545-554.
-
Seto AH, Rollefson W, Patel MP, Suh WM, Tehrani DM, Nguyen JA, Amador DG, Behnamfar O, Garg V, Cohen MG. Radial haemostasis is facilitated with a potassium ferrate haemostatic patch: the Statseal with TR Band assessment trial (STAT). EuroIntervention. 2018 Dec 07; 14(11):e1236-e1242.
-
Ren X, Evangelista-Leite D, Wu T, Rajab TK, Moser PT, Kitano K, Economopoulos KP, Gorman DE, Bloom JP, Tan JJ, Gilpin SE, Zhou H, Mathisen DJ, Ott HC. Metabolic glycan labeling and chemoselective functionalization of native biomaterials. Biomaterials. 2018 11; 182:127-134.
-
Ashfaq A, Soroya MS, Iyengar A, Federman M, Reemtsen BL. Heparin-Coated Grafts Reduce Mortality in Pediatric Patients Receiving Systemic-to-Pulmonary Shunts. Pediatr Cardiol. 2018 Mar; 39(3):473-477.
-
Saad M, Nairooz R, Rashed A, Abdelaziz HK, Mentias A, Abbott JD. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials. Cardiovasc Revasc Med. 2017 Sep; 18(6):418-424.
-
Omran J, Abdullah O, Abu-Fadel M, Gray WA, Firwana B, Drachman DE, Mahmud E, Aronow HD, White CJ, Al-Dadah AS. Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):746-753.
-
Ayoub K, Nairooz R, Almomani A, Marji M, Paydak H, Maskoun W. Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis. J Stroke Cerebrovasc Dis. 2016 Sep; 25(9):2215-21.
-
Karakala N, Tolwani A. We Use Heparin as the Anticoagulant for CRRT. Semin Dial. 2016 07; 29(4):272-4.
-
Li J, Pan Q, Rowan PD, Trotter TN, Peker D, Regal KM, Javed A, Suva LJ, Yang Y. Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget. 2016 Mar 08; 7(10):11299-309.
-
Niebler RA, Woods KJ, Murkowski K, Ghanayem NS, Hoffman G, Mitchell ME, Punzalan RC, Scott JP, Simpson P, Tweddell JS. A Pilot Study of Antithrombin Replacement Prior to Cardiopulmonary Bypass in Neonates. Artif Organs. 2016 Jan; 40(1):80-5.
-
Pandey S, Drobena G, Cottler-Fox M. TRANSFUSION MEDICINE ILLUSTRATED. Heparin-induced thrombocytopenia: a cautionary tale. Transfusion. 2015 Dec; 55(12):2790.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|